Prevention of Atherothrombotic Brain Infarction: Role of Lipids

  • Frank M. Yatsu
  • Thomas J. DeGraba


Atherothrombotic brain infarction (ABI) is the primary cause of stroke both in the Western and Eastern worlds. The apparent successes of interventional measures in averting coronary atherosclerosis has fueled interest and optimism in applying these strategies to ABIs, both for primary and secondary prevention.1 The magnitude of ABIs worldwide and the frustration in having no reliable or effective acute therapies to prevent ischemic brain injury have led to greater efforts to reduce the primary disease of atherosclerosis.1 Therapeutic approaches in the past for ABI prevention have evolved behind those for coronary heart disease (CHD) and include surgical, medical, and “holistic” interventions through risk reduction.


Coronary Heart Disease Carotid Stenosis Reverse Cholesterol Transport Lipid Research Clinic Multiple Risk Factor Intervention Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Yatsu FM, Fisher M. Atherosclerosis: current concepts on pathogenesis and interventional therapies. Ann Neurol. 1989;26:3–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Grotta JC. Current medical and surgical therapy for cerebrovascular disease. N Engl J Med. 1987;316: 1505–1516.CrossRefGoogle Scholar
  3. 3.
    The Asymptomatic Carotid Atherosclerosis Study Group. Study design for randomization prospective trial of carotid endarterectomy for asymptomatic atherosclerosis. Stroke. 1989;20:844–849.CrossRefGoogle Scholar
  4. 4.
    The EC/IC bypass Study Group. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: results of an international randomized trial. N Engl J Med. 1985;313:1191–1200.CrossRefGoogle Scholar
  5. 5.
    Fields WS, Lemak NA, et al. Controlled trial of aspirin in cerebral ischemia. Stroke. 1977;8:301–316.PubMedCrossRefGoogle Scholar
  6. 6.
    The American-Canadian Co-operative Study Group. Persantine aspirin trial in cerebral ischemia, part IL Endpoint results. Stroke. 1985; 16: 406–415.CrossRefGoogle Scholar
  7. 7.
    UK-TIA Study Group. United Kingdom transient ischemic attack (UK-TIA) aspirin trial: interim results. Br Med J. 1988;296:316–320.CrossRefGoogle Scholar
  8. 8.
    Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing Ticlopidine Hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med. 1989;321:501–507.PubMedCrossRefGoogle Scholar
  9. 9.
    Grundy SM, Greenland P, et al. Cardiovascular and risk factor evaluation of healthy American adults-a statement for physicians by an ad hoc committee appointed by the steering committee, American Heart Association. Circulation. 1987; 75:1340A- 1362A.PubMedGoogle Scholar
  10. 10.
    Kannel WB, McGee DC. Diabetes and cardiovascular disease: the Framingham study. JAMA. 1979;241:2035–2038.PubMedCrossRefGoogle Scholar
  11. 11.
    Strategies for the prevention of coronary heart disease: a policy statement of the European Atherosclerosis Society. Eur Heart J. 1987;8:77–88.Google Scholar
  12. 12.
    Castelli WP, Garrison RJ, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA. 1986;256: 2835–2838.PubMedCrossRefGoogle Scholar
  13. 13.
    Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365–374.CrossRefGoogle Scholar
  14. 14.
    Leon AS, Connett J, et al. Leisure-time physical activity levels and risk of coronary heart disease and death: The multiple risk factor intervention trial. JAMA. 1987;258:2388–2395.PubMedCrossRefGoogle Scholar
  15. 15.
    Kannel WB, Wilson P, Blair SN. Epidemiological assessment of the role of physical activity and fitness in the development of cardiovascular disease. Am Heart J. 1985;109:876–885.PubMedCrossRefGoogle Scholar
  16. 16.
    Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings: III. Reduction in stroke incidence among persons with high blood pressure. JAMA. 1982;247:663–683.Google Scholar
  17. 17.
    Whelton PK. Declining mortality from hypertension and stroke. South Med J. 1982;75:33–38.PubMedCrossRefGoogle Scholar
  18. 18.
    The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251: 351–364.CrossRefGoogle Scholar
  19. 19.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: Primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors and incidence of coronary heart disease. N Engl J Med. 1987;317: 1237 - 1245.PubMedCrossRefGoogle Scholar
  20. 20.
    Grotta JC, Yatsu FM, et al. Prediction of carotid stenosis progression by lipid and hematological measurements. Neurology. 1989;39:1325–1331.PubMedCrossRefGoogle Scholar
  21. 21.
    Yatsu FM, Becker C, McLeroy KR, et al. Community hospital based stroke programs: North Carolina, Oregon and New York: I. Goals, objectives and data collection procedures. Stroke. 1986;17:276–284.PubMedCrossRefGoogle Scholar
  22. 22.
    Abbott RD, Donahue RP, et al. Diabetes and the risk of stroke: the Honolulu heart program. JAMA. 1987;257:949–952.PubMedCrossRefGoogle Scholar
  23. 23.
    Kannel WB, Wolf PA, McGee DL, et al. Systolic blood pressure, arterial rigidity and risk of stroke: the Framingham study. JAMA. 1981 ;245:1225–1229.PubMedCrossRefGoogle Scholar
  24. 24.
    Price TR, Dambrosia J, et al. Early determination of prognosis for 30 day and 1 year survival in ischemic infarction. The NINCDS stroke data bank. Neurology. 1985;35 (suppl 1):212.CrossRefGoogle Scholar
  25. 25.
    Sacco RL, Foulkes MA, Mohr JP, et al. Determinants of early recurrence of cerebral infarction: stroke data bank. Stroke. 1988; 19:144.Google Scholar
  26. 26.
    Dexter DD Jr, Whisnant JP, et al. The association of stroke and coronary heart disease: a population study. Mayo Clin Proc. 1987;62:1077–1083.PubMedCrossRefGoogle Scholar
  27. 27.
    Abbott RD, Yin Y, Reed DM, et al. Risk of stroke in male cigarette smokers. N Engl J Med. 1986; 315:717–720.PubMedCrossRefGoogle Scholar
  28. 28.
    Stampfer MJ, Colditz GA, et al. A prospective study of moderate alcohol consumption and the risk of coronary disease and stroke in women. N Engl J Med. 1988;319:267–213.PubMedCrossRefGoogle Scholar
  29. 29.
    Gill J, Zezuika, AV, et al. Stroke and alcohol consumption. N Engl J Med. 1986;315:1041–1046.PubMedCrossRefGoogle Scholar
  30. 30.
    Fry DL, Manley RW, Oh SY, Smyt CR. Aortic transmural serum protein transport: effect of concentration time and location. Am J Physiology. 1981;241:1454–1461.Google Scholar
  31. 31.
    Gordon, T. The Framingham diet study: diet and the regulation of serum cholesterol. In: Kannel WB, Gordon T, eds. Framingham Study: An Epidemiological Investigation of Cardiovascular Disease. Section 24. Washington, DC: Government Printing Office; 1970.Google Scholar
  32. 32.
    Steinberg D. Lipoproteins and the pathogenesis of atherosclerosis. Circulation. 1987;76:508–514.PubMedCrossRefGoogle Scholar
  33. 33.
    Mahley RW. Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol. Med Clin North Am. 1982;66:375–400.PubMedGoogle Scholar
  34. 34.
    Ross R. The pathogenesis of atherosclerosis —an update. N Engl J Med. 1986;295:369–377.CrossRefGoogle Scholar
  35. 35.
    Jonasson L, Holm J, Skalli O, et al. Regional accumulation of T cells, macrophages and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6:131–138.PubMedCrossRefGoogle Scholar
  36. 36.
    Ross R, Glomset J, Kariya B, et al. A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro. Proc Natl Acad Sci USA. 1974;71:1207–1210.PubMedCrossRefGoogle Scholar
  37. 37.
    Joris I, Zand T, Nunnari JJ, et al. Studies on the pathogenesis of atherosclerosis: I. Adhesion and emigration of mononuclear cells in the aorta of hypercholesterolemic rats. Am J Pathol. 1983; 113: 341–385.PubMedGoogle Scholar
  38. 38.
    Brown MS, Goldstein JL. Lipoprotein metabolism in macrophages: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983;52: 223–261.PubMedCrossRefGoogle Scholar
  39. 39.
    Fielding CJ, Fielding PE. Cholesterol transport between cells and body fluids. Med Clin North Am. 1982;66:363–373.PubMedGoogle Scholar
  40. 40.
    Schmitz G, Niemann R, Brennhausen B, et al. Regulation of high density lipoprotein receptors in cultured macrophages: role of acyl-CoA: cholesterol acyltransferase. EMBO J. 1985;4:2773–2779.PubMedGoogle Scholar
  41. 41.
    Stein O, Halperin G, Stein Y: Cholesteryl ester efflux from extracellular and cellular elements of the arterial wall. Arteriosclerosis. 1986;6:70–78.PubMedCrossRefGoogle Scholar
  42. 42.
    Miller GM, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet. 1975;1:16–18.PubMedCrossRefGoogle Scholar
  43. 43.
    Rossner S, Kjellin KG, Mettinger KL, et al. Normal serum cholesterol but low high density lipoprotein cholesterol concentrations in young patients with ischaemic cerebrovascular disease. Lancet. 1978; 1: 577–579.PubMedCrossRefGoogle Scholar
  44. 44.
    Sirtori CR, Gainfrancheschi G, Gritti I, et al. Decreased levels of high-density lipoprotein cholesterol levels in male patients with transient ischemic attacks. Atherosclerosis. 1979;30:205–211.CrossRefGoogle Scholar
  45. 45.
    Taggart H, Stout RW. Reduced high density lipoprotein in stroke: relationship with elevated triglyceride and hypertension. Eur J Clin Invest. 1979; 9:219–221.PubMedCrossRefGoogle Scholar
  46. 46.
    Noma A, Matshushita S, Komori T, et al. High and low density lipoprotein cholesterol in myocardial and cerebral infarction. Atherosclerosis. 1979;32: 327–331.PubMedCrossRefGoogle Scholar
  47. 47.
    Nubiola AR, Masana L, Masdeu S, et al. High density lipoprotein but low high density lipoprotein cholesterol concentrations in young patients with ischaemic cerebrovascular disease. Lancet. 1978; 1: 577–579.Google Scholar
  48. 48.
    Bihari-Varga M, Szekely J, Gruber E. Plasma high density lipoproteins in coronary, cerebral and peripheral vascular disease: the influence of various risk factors. Atherosclerosis. 1981;40:337–345.PubMedCrossRefGoogle Scholar
  49. 49.
    Murai A, Tanaka T, Miyahara T, Kameyama M. Lipoprotein abnormalities in the pathogenesis of cerebral infarction and transient ischemic attack. Stroke. 1981;12:167–172.PubMedCrossRefGoogle Scholar
  50. 50.
    Brinton, EA, Eisenberg S, Breslow JL. Elevated high density lipoprotein cholesterol levels correlate with decreased apolipoprotein A-l and A-II fractional catabolic rate in women. J Clin Invest. 1989; 84:262–269.PubMedCrossRefGoogle Scholar
  51. 51.
    Yatsu FM, Alam R, Alam S. Scavenger activity in monocyte-derived macrophages from atherothrom-botic strokes. Stroke. 1986;17:709–713.PubMedCrossRefGoogle Scholar
  52. 52.
    Hartung HP, Kladetzky RG, Melnik B, et al. Stimulation of the scavenger receptor on monocyte-macrophage evokes release of arachidonic acid metabolites and reduced oxygen species. Lab Invest. 1986;55:209–216.PubMedGoogle Scholar
  53. 53.
    Gerrity RG. The role of the monocyte in atherogene-sis: I. Transition of blood-borne monocytes into foam cells in fatty lesions. Am J Pathol. 1981; 103:181–190.PubMedGoogle Scholar
  54. 54.
    Van Lenten BJ, Fogelman AM, Jackson RL, et al. Receptor-mediated uptake of remnant lipoproteins by cholesterol-loaded human monocyte-macrophages. J Biol Chem. 1985;260:8783–8788.PubMedGoogle Scholar
  55. 55.
    Wissler RW. Principles of the pathogenesis of atherosclerosis. In: Braunwald E. ed. Heart Disease. Philadelphia, PA: W.B. Saunders Co.; 1980: pp 1221–1245.Google Scholar
  56. 56.
    Faggiotto A, Ross R, Harker L: Studies of hypercholesterolemia in the nonhuman primate: II. Fatty streak conversion to fibrous plaque. Arteriosclerosis. 1984;45:341–356.Google Scholar
  57. 57.
    Malinow MR, Blaton V. Regression of atherosclerotic lesions. Arteriosclerosis. 1984;4:292–295.PubMedCrossRefGoogle Scholar
  58. 58.
    Salonen JT, Puska P, Mustaniemi H. Changes in morbidity and mortality during comprehensive community programme to control cardiovascular diseases during 1972–77 in North Karelia. Br Med J. 1979;2:1178–1183.PubMedCrossRefGoogle Scholar
  59. 59.
    West RO, Hayes OB. Diet and serum cholesterol levels: a comparison between vegetarians and non-vegetarians in a Seventh Day Adventist group. Am J Clin Nutr. 1986;21:853.Google Scholar
  60. 60.
    Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986; 232:34–47.PubMedCrossRefGoogle Scholar
  61. 61.
    Keys A. Coronary heart disease in seven countries. Circulation. 1970;41 (suppl 1): 1–8.Google Scholar
  62. 62.
    Havel RJ. Classification of hyperlipidemias. Ann Rev Med. 1977;28:195–209.PubMedCrossRefGoogle Scholar
  63. 63.
    Scanu AM. Lipoprotein (a): A potential bridge between the fields of atherosclerosis and thrombosis. Arch Pathol Lab Med. 1988; 112:1045–1047.PubMedGoogle Scholar
  64. 64.
    Zenker G, Koltringer P, Bone G, et al. Lipoprotein (a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17:942–945.PubMedCrossRefGoogle Scholar
  65. 65.
    van Berkel JC, Bakkeren HF, Kuipers F, et al. In vivo evidence for reverse cholesterol transport from liver endothelial cells to parenchymal cells and bile by high density lipoproteins. Tenth International Symposium on Drugs Affecting Lipid Metabolism; November 8–11, 1989:47. Abstract 223.Google Scholar
  66. 66.
    Alam R, Yatsu FM, Tsui L, Alam S. Receptor-mediated uptake and “retroendocytosis” of high-density lipoproteins by cholesterol-loaded human monocyte-derived macrophages: possible role in enhancing reverse cholesterol transport. Biochimica et Biophysica Acta. 1989;1004:292–299.PubMedCrossRefGoogle Scholar
  67. 67.
    Brunzell JD, Sniderman AD, Albers JJ, et al. Apoproteins B and A-I and coronary heart disease. Arteriosclerosis. 1984;4:79–83.PubMedCrossRefGoogle Scholar
  68. 68.
    Wallentin L, Sundin B. HDL2 and HDL3 lipid levels in coronary heart disease and other causes. Atherosclerosis. 1986;59:3–104.CrossRefGoogle Scholar
  69. 69.
    Norum RA, Lakier JB, Goldstein S, et al. Familial deficiency of apolipoprotein A-I and C-III and precocious coronary heart disease. N Engl J Med. 1986; 306:1513–1519.CrossRefGoogle Scholar
  70. 70.
    Karathanasis SK, Zannis VI, Breslow JL. A DNA insertion in the human apoprotein A-I gene locus related to the development of atherosclerosis. Nature. 1983;301:718.PubMedCrossRefGoogle Scholar
  71. 71.
    Rees A, Stocks J, Sharpe CR, et al. DNA polymorphism in the apoprotein A-I-CIII gene cluster. J Clin Invest. 1995;76:1090–1095.CrossRefGoogle Scholar
  72. 72.
    Roederer GD, Langlois YE, Jagar KA, et al. The natural history of carotid arterial disease in asymptomatic patients with cervical bruits. Stroke. 1984; 15:605–613.PubMedCrossRefGoogle Scholar
  73. 73.
    Garg A, Grundy SM. Lovastatin for lowering cholesterol levels in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988;318:81–86.PubMedCrossRefGoogle Scholar
  74. 74.
    Bilheimer DW, Grundy SW, Brown MS, et al. Mevinolin and colestipol stimulate receptor-mediated clearance in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA. 1983;80: 4124–4128.PubMedCrossRefGoogle Scholar
  75. 75.
    Multiple Risk Factor Intervention Trial Research Group. Risk factor changes and mortality results. JAMA. 1982;248:1465–1477.CrossRefGoogle Scholar
  76. 76.
    Moore, TJ. The cholesterol myth. Atlantic Monthly. September 1989. pp 37–70.Google Scholar
  77. 77.
    Brett A. Treating hypercholesterolemia —how should practicing physicians interpret the published data for patients? N Engl J Med. 1989;321:676–680.PubMedCrossRefGoogle Scholar
  78. 78.
    Leaf A. Management of hypercholesterolemia—are creative interventions advisable? TV Engl J Med. 321:680–684.Google Scholar
  79. 79.
    Mensink RP, Katan MB. Effects of a diet enriched with monounsaturated or polyunsaturated fatty acids on levels of low-density and high density lipoprotein cholesterol in healthy women and men. N Engl J Med. 1989;321:436–441.PubMedCrossRefGoogle Scholar
  80. 80.
    Mattson FH, Grundy SM. Comparison of effects of dietary saturated, monounsaturated and polyunsaturated fatty acids on plasma lipids and lipoproteins in man. J Lipid Res. 1985;26:194–202.PubMedGoogle Scholar
  81. 81.
    AHA Special Report. Recommendations for the treatment of hyperlipidemia in adults: a joint statement of the Nutrition Committee and the Council on Arteriosclerosis. Circulation. 1984;69, 1065A.Google Scholar
  82. 82.
    Consensus Conference. Lowering blood cholesterol to prevent heart disease. JAMA. 1985;253:2080–2086.CrossRefGoogle Scholar
  83. 83.
    American Heart Association Committee Report. Rationale of the diet-heart statement of the American Heart Association. Circulation. 1982;65:839–854.CrossRefGoogle Scholar
  84. 84.
    Strategy for the Prevention of Coronary Heart Disease. A policy statement of the European Atherosclerosis Society. Eur Heart J. 1987;8:77–88.Google Scholar
  85. 85.
    Hoeg JM, Gregg RE, Brewer HBV Jr. An approach to the management of hyperlipoproteinemias. JAMA. 1986;255:512.PubMedCrossRefGoogle Scholar
  86. 86.
    Yatsu FM, Alam R, Alam S. Enhancement of cholesteryl ester metabolism in cultured human monocyte-derived macrophages by Verapamil. Biochim Biophys Acta. 1985;847:77–81.PubMedCrossRefGoogle Scholar
  87. 87.
    Kramsch DM, Aspen AJ, Apstein CS. Suppression of experimental atherosclerosis by the calcium antagonist lanthanum. Possible role of calcium in atherogenesis. J Clin Invest. 1980;65:967–981.PubMedCrossRefGoogle Scholar
  88. 88.
    Parmley WW, Blumlein S, Sievers R. Modification of experimental atherosclerosis by calcium channel blockers. Am J Cardiol. 1985;55:165B-171B.PubMedCrossRefGoogle Scholar
  89. 89.
    Betz E, Hammerle H, Strohschneider T. Inhibition of smooth muscle cell proliferation and endothelial cell permeability with Flunarizine in vitro and in experimental atheromas. Res Exp Med. 1985; 185: 325–340.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1991

Authors and Affiliations

  • Frank M. Yatsu
  • Thomas J. DeGraba

There are no affiliations available

Personalised recommendations